NZ590146A - Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor - Google Patents

Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor

Info

Publication number
NZ590146A
NZ590146A NZ590146A NZ59014609A NZ590146A NZ 590146 A NZ590146 A NZ 590146A NZ 590146 A NZ590146 A NZ 590146A NZ 59014609 A NZ59014609 A NZ 59014609A NZ 590146 A NZ590146 A NZ 590146A
Authority
NZ
New Zealand
Prior art keywords
terminal
receptor
region
epitope
residue
Prior art date
Application number
NZ590146A
Other languages
English (en)
Inventor
Julian Alexander Barden
Angus Gidley-Baird
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903451A external-priority patent/AU2008903451A0/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Publication of NZ590146A publication Critical patent/NZ590146A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ590146A 2008-07-04 2009-07-03 Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor NZ590146A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Publications (1)

Publication Number Publication Date
NZ590146A true NZ590146A (en) 2012-09-28

Family

ID=41465424

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590146A NZ590146A (en) 2008-07-04 2009-07-03 Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor

Country Status (12)

Country Link
US (3) US8597643B2 (enExample)
EP (1) EP2318438B1 (enExample)
JP (2) JP5701752B2 (enExample)
KR (1) KR101701300B1 (enExample)
CN (1) CN102143978B (enExample)
AU (1) AU2009266430B2 (enExample)
BR (1) BRPI0915367B8 (enExample)
CA (1) CA2729868C (enExample)
ES (1) ES2610225T3 (enExample)
IL (2) IL210220A (enExample)
NZ (1) NZ590146A (enExample)
WO (1) WO2010000041A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
JP5670192B2 (ja) * 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド 新規ｐ２ｘ７エピトープ
KR101701300B1 (ko) 2008-07-04 2017-02-01 바이오셉터 (어스트) 피티와이 엘티디 항­ｐ２ｘ７ 펩티드 및 에피토프
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
BR112012015561B1 (pt) 2009-12-24 2019-11-12 Biosceptre International Ltd anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
JP6790062B2 (ja) * 2015-04-02 2020-11-25 バイオセプター・（ユーケー）・リミテッド 疼痛治療
KR20180043841A (ko) * 2015-09-11 2018-04-30 카리나 바이오테크 피티와이 엘티디 키메라 항원 수용체 및 이의 용도
WO2018071959A1 (en) 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles
BR112023020659A2 (pt) * 2021-04-08 2023-12-05 Biosceptre Aust Pty Ltd Métodos para controlar a atividade de célula imune
JP2025531021A (ja) * 2022-09-14 2025-09-19 バイオセプター （オースト） プロプライエタリー・リミテッド 免疫細胞を検出する方法
CN120187747A (zh) * 2022-09-14 2025-06-20 生物权威(澳大利亚)有限责任公司 工程化免疫细胞的富集
JP2025531030A (ja) * 2022-09-14 2025-09-19 バイオセプター （オースト） プロプライエタリー・リミテッド 免疫細胞のインビボ検出

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
EP0760850A1 (en) 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
EP0854923A2 (en) 1995-08-09 1998-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
WO1997041222A1 (en) 1996-04-30 1997-11-06 Smithkline Beecham P.L.C. HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US6329503B1 (en) * 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU2001274902A1 (en) * 2000-12-06 2002-06-18 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
AU2002322192B2 (en) 2001-09-03 2008-05-01 Biosceptre International Limited Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
DK1473367T3 (da) 2003-04-17 2007-10-01 Affectis Pharmaceuticals Ag Midler og fremgangsmåder til diagnosticering og behandling af effektive lidelser
CA2607541A1 (en) * 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
ATE542139T1 (de) * 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
JP5670192B2 (ja) * 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド 新規ｐ２ｘ７エピトープ
KR101701300B1 (ko) 2008-07-04 2017-02-01 바이오셉터 (어스트) 피티와이 엘티디 항­ｐ２ｘ７ 펩티드 및 에피토프
ES2904911T3 (es) * 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
BR112012015561B1 (pt) 2009-12-24 2019-11-12 Biosceptre International Ltd anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy

Also Published As

Publication number Publication date
JP5701752B2 (ja) 2015-04-15
US20110110959A1 (en) 2011-05-12
US20160199442A1 (en) 2016-07-14
ES2610225T3 (es) 2017-04-26
CN102143978B (zh) 2015-02-18
BRPI0915367B1 (pt) 2020-10-13
BRPI0915367B8 (pt) 2021-05-25
US9328155B2 (en) 2016-05-03
BRPI0915367A2 (pt) 2015-11-03
KR101701300B1 (ko) 2017-02-01
IL210220A (en) 2016-04-21
IL232394A0 (en) 2014-06-30
IL232394A (en) 2016-04-21
US8597643B2 (en) 2013-12-03
CN102143978A (zh) 2011-08-03
US20140135475A1 (en) 2014-05-15
EP2318438A4 (en) 2012-11-21
CA2729868A1 (en) 2010-01-07
EP2318438A1 (en) 2011-05-11
WO2010000041A1 (en) 2010-01-07
IL210220A0 (en) 2011-03-31
AU2009266430A8 (en) 2011-03-10
EP2318438B1 (en) 2016-11-02
AU2009266430B2 (en) 2014-08-14
JP2015038144A (ja) 2015-02-26
CA2729868C (en) 2018-07-10
US10238716B2 (en) 2019-03-26
JP2011526249A (ja) 2011-10-06
KR20110031222A (ko) 2011-03-24
AU2009266430A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
NZ590146A (en) Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor
JP2011526249A5 (enExample)
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
WO2009059804A3 (en) T-cell receptor peptides specific for part of cd20, uses thereof, and methods of preparing cytotoxic t-cells
NZ610075A (en) Cxcr2 binding polypeptides
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PE20081625A1 (es) Proteinas de union al antigeno del receptor a de la il-17
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
IL296062A (en) Antibodies against muc16 and their uses
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
MX2009010120A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
RU2015106749A (ru) Конструирование т-клеточных рецепторов
NZ592151A (en) Anti-igf antibodies
NZ585622A (en) Hepatitis c virus antibodies
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
IN2012DN02535A (enExample)
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
WO2005056600B1 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
IL212056A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2008136736A3 (en) Immunoregulatory structures from normally occurring proteins
NZ603712A (en) Antibodies containing therapeutic tpo/epo mimetic peptides
NZ597611A (en) Anti notch-1 antibodies
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
WO2011108008A3 (en) Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 JUL 2016 BY FREEHILLS PATENT ATTORNEYS

Effective date: 20130603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2017 BY FREEHILLS PATENT ATTORNEYS

Effective date: 20160602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2018 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20170602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2019 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20180604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2020 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20190531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2021 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20200603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2022 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20210603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2023 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20220602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2024 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20230602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2025 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20240603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2026 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20250602